RxDoctor Payments Data

Edwin Hollins, MD

Internal Medicine · Blue Island, ILNPI 1982721643

Payments from drug & device makers

$424in general payments, 2019–2025

Across 23 payments — averaging $18.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$96
  • GSK$67
  • AstraZeneca$63
  • Novartis$62
  • Lilly USA, LLC$47
  • Merck$25
  • plus $64 from 4 others

What the payments were for

  • Food & beverage$424100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novo Nordisk5$96
GSK4$67
AstraZeneca3$63
Novartis4$62
Lilly USA, LLC2$47
Merck1$25
Pfizer1$23
Amgen1$14
Abbott1$14
Dexcom, Inc.1$14

How this compares

$424 in reported general payments places this provider in the 65th percentile of 5,182 internal medicine providers in Illinois.

See all internal medicine providers in Illinois

Medicare billing

Part B allowed, 2024
$26,069
Medicare patients
107
Services billed
329

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban96$89,748
OzempicSemaglutide56$66,991
RybelsusSemaglutide38$53,022
JardianceEmpagliflozin54$43,492
Trelegy ElliptaFluticasone/Umeclidin/Vilanter49$32,275
EntrestoSacubitril/Valsartan20$31,673
JanuviaSitagliptin Phosphate38$31,004
XareltoRivaroxaban32$30,113
TrulicityDulaglutide13$17,181
Tresiba Flextouch U-100Insulin Degludec18$15,671
SymbicortBudesonide/Formoterol Fumarate23$8,897
Albuterol Sulfate HfaAlbuterol Sulfate188$7,558
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog19$6,508
Arnuity ElliptaFluticasone Furoate11$5,249
Atorvastatin Calcium626$4,766

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$96$120,01494 claims
PfizerEliquis, Premarin$23$93,140108 claims
GSKTrelegy Ellipta, Arnuity Ellipta$67$37,52460 claims
NovartisEntresto$62$31,67320 claims
MerckJanuvia$25$31,00438 claims
Lilly USA, LLCTrulicity$47$17,18113 claims
AstraZenecaSymbicort$63$8,89723 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 5,182 internal medicine providers in Illinois.

Other internal medicine in Blue Island

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →